(Q73897707)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10854652%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

title

Extended observations on MS patients treated with IM interferon-beta1a (Avonex): implications for modern MS trials and therapeutics (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10854652%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

author name string

L Jacobs

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10854652%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

R Rudick

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10854652%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

J Simon

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10854652%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

publication date

1 July 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10854652%20AND%20SRC:MED&resulttype=core&format=json

Journal of Neuroimmunology

7 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10854652%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

volume

107

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10854652%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10854652%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

page(s)

167-173

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10854652%20AND%20SRC:MED&resulttype=core&format=json

Suppression of experimental allergic encephalomyelitis by interferon

7 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900232-0

7 January 2021

Interferon-beta impairs induction of HLA-DR antigen expression in cultured adult human astrocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900232-0

7 January 2021

Design strategies in multiple sclerosis clinical trials. The Cyclosporine Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900232-0

7 January 2021

The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900232-0

7 January 2021

Expression of interferon-induced genes in different tissues of mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900232-0

7 January 2021

Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Multiple Sclerosis Collaborative Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900232-0

7 January 2021

Effect of rat and beta-human interferons on hyperacute experimental allergic encephalomyelitis in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900232-0

7 January 2021

Contrasting effect of alpha/beta- and gamma-interferons on expression of macrophage Ia antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900232-0

7 January 2021

Intrathecal Interferon Reduces Exacerbations of Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900232-0

7 January 2021

Intrathecal interferon in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900232-0

7 January 2021

Multicentre double-blind study of effect of intrathecally administered natural human fibroblast interferon on exacerbations of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900232-0

7 January 2021

Intrathecally administered natural human fibroblast interferon reduces exacerbations of multiple sclerosis. Results of a multicenter, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900232-0

7 January 2021

A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG).

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900232-0

7 January 2021

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900232-0

7 January 2021

Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900232-0

7 January 2021

Interferon beta augments suppressor cell function in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900232-0

7 January 2021

Interferon-beta specifically inhibits interferon-gamma-induced class II major histocompatibility complex gene transcription in a human astrocytoma cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900232-0

7 January 2021

In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon beta

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900232-0

7 January 2021

Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900232-0

7 January 2021

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900232-0

7 January 2021

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900232-0

7 January 2021

Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900232-0

7 January 2021

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900232-0

7 January 2021

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900232-0

7 January 2021

A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900232-0

7 January 2021

Axonal transection in the lesions of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900232-0

7 January 2021

The interferons: biological effects, mechanisms of action, and use in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900232-0

7 January 2021

Inducible expression of H-2 and Ia antigens on brain cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900232-0

7 January 2021

10.1016/S0165-5728(00)00232-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10854652%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference